Safety of Recombinant Human C1 Esterase Inhibitor for Hereditary Angioedema Attacks During Pregnancy.

[1]  M. Vlková,et al.  Treatment of Hereditary Angioedema Attacks with Icatibant and Recombinant C1 Inhibitor During Pregnancy , 2018, Journal of Clinical Immunology.

[2]  R. Lockey,et al.  The international WAO/EAACI guideline for the management of hereditary angioedema—The 2017 revision and update , 2018, Allergy.

[3]  William H. Yang,et al.  Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial , 2017, The Lancet.

[4]  J. Edelman,et al.  Safety of a C1-inhibitor concentrate in pregnant women with hereditary angioedema. , 2017, Allergy and asthma proceedings.

[5]  J. Bernstein,et al.  Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[6]  Tom Bowen,et al.  International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. , 2012, The Journal of allergy and clinical immunology.

[7]  J. Nuijens,et al.  Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. , 2010, The Journal of allergy and clinical immunology.

[8]  H. Farkas,et al.  The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey. , 2010, European journal of obstetrics, gynecology, and reproductive biology.

[9]  T. Klingebiel,et al.  Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. , 2010, American journal of obstetrics and gynecology.